Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcSé Pembrolizumab for Rare Cancers
NCT03012620Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2017
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in sarcoma, ovarian cancer, primary central nervous system lymphoma (PCNSL) and 4 more, sponsored by Unicancer. Primary endpoint: Objective Response Rate at Day 84. Started Jul 2017; status: completed.
02
Drugs
03
Conditions
sarcomaovarian cancerprimary central nervous system lymphoma (PCNSL)thyroid cancerNeuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT03012620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012620.